Johnson & Johnson JNJ

$264.74 -2.83 (-1.06%)

Valuation

Market cap
655,371,776,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.97
Forward PE
23.37
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,086,053
Avg volume
6,709,686
Day's range
$264.51 – $268.48
Shares out
2,409,898,000
Stochastic %K
25%
Beta
0.24
Analysts
Strong Sell
Price target
$281.08

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Investor203 Sep 30, 7:07 PM
$VNDA $LLY $JNJ .. someone going to BO at $20-$25 soon.
0 replies
tonyp262 Sep 30, 6:45 PM
$JNJ surprised this is getting beat down today. Should be looking back up to 268 by end of day tomorrow.
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:31 PM
$AZN $BMY $JNJ $PFE $SLS With Warrants Extinguished and No real resistance can move to the upside very violently. Tis the evening before what we all here have been waiting for. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:21 PM
$AZN $BMY $JNJ $PFE $SLS This move up is on very heavy volume. No big resistance till $15.87. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:02 PM
$AZN $BMY $JNJ $PFE $SLS Ask being chewed up, Big block buys going through Level 2. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 5:33 PM
$ABBV $BMY $JNJ $PFE $SLS Pfizer CEO Dr. Bourla friend of Sellas CEO Dr. Stergiou. Dr. Bourla Cancer is not one disease. It hides, it adapts, it comes back different. That is why the research is so complicated, and why it has remained the greatest challenge in medicine. But the science is breaking, and we can now see opportunities to defeat it that we could not even dream of a few years ago. Going after a problem that big takes focus, and the same is true for all of us, whatever your goal may be. Focus enables ambition. When it is guided by real purpose, you can go further than you ever thought possible. That is why we dedicate the greatest share of our research to cancer, and why I am more optimistic than ever about what that will mean for patients. On #WorldCancerResearchDay, my thanks to every researcher working to get us there. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 4:36 PM
$ABBV $BMY $JNJ $PFE $SLS 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Sep 30, 4:23 PM
$AZN $BMY $JNJ $PFE $SLS Sellas BOD Katherine Bach is A deep immunotherapy expert. Previously at Celgene (sold to BMS for $74 BILLION)worked with Mr. Cavanaugh to facilitate the biggest deal in over a decade. Experienced in AML, hematology, cell therapies Very familiar with survival data patterns & regulatory signals. Katherine Bach 3 cluster purchases last year before the BO conversations started. ✌️🙏❤️‍🩹
0 replies